Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Burning Rock Biotech (BNR) Non-Current Assets: 2019-2025

Historic Non-Current Assets for Burning Rock Biotech (BNR) over the last 4 years, with Sep 2025 value amounting to $912,000.

  • Burning Rock Biotech's Non-Current Assets fell 34.15% to $912,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $912,000, marking a year-over-year decrease of 34.15%. This contributed to the annual value of $14.9 million for FY2024, which is 32.19% down from last year.
  • Burning Rock Biotech's Non-Current Assets amounted to $912,000 in Q3 2025, which was down 88.34% from $7.8 million recorded in Q1 2025.
  • Burning Rock Biotech's 5-year Non-Current Assets high stood at $71.8 million for Q4 2021, and its period low was $500,000 during Q1 2024.
  • Its 3-year average for Non-Current Assets is $8.3 million, with a median of $9.3 million in 2023.
  • Its Non-Current Assets has fluctuated over the past 5 years, first crashed by 95.68% in 2024, then spiked by 1,464.40% in 2025.
  • Burning Rock Biotech's Non-Current Assets (Quarterly) stood at $71.8 million in 2021, then crashed by 33.64% to $47.7 million in 2022, then plummeted by 53.92% to $22.0 million in 2023, then plummeted by 32.19% to $14.9 million in 2024, then crashed by 34.15% to $912,000 in 2025.
  • Its Non-Current Assets stands at $912,000 for Q3 2025, versus $7.8 million for Q1 2025 and $14.9 million for Q4 2024.